We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
Cap. Flow
-$10.3M
Cap. Flow %
-0.37%
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.7M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$13.3M
5
JNJ icon
Johnson & Johnson
JNJ
+$11.2M

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$23.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$12.8M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
AMGN icon
Amgen
AMGN
+$11.4M
5
AKRX
Akorn Inc
AKRX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Real Estate 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMK
101
DELISTED
GenMark Diagnostics, Inc
GNMK
$2.84M 0.1%
294,749
+201,400
+216% +$2.09M
MNTA
102
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.83M 0.1%
152,900
– –
ACHN
103
DELISTED
Achillion Pharmaceuticals
ACHN
$2.77M 0.1%
+616,000
New +$2.74M
THC icon
104
Tenet Healthcare
THC
$21.8B
$2.7M 0.1%
164,500
-148,940
-48% -$2.53M
TRIL
105
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.58M 0.09%
500,000
– –
JUNO
106
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.55M 0.09%
56,900
– –
IPXL
107
DELISTED
Impax Laboratories, Inc.
IPXL
$2.52M 0.09%
124,335
– –
SNDX icon
108
Syndax Pharmaceuticals
SNDX
$1.73B
$2.34M 0.08%
200,000
– –
CDTX
109
DELISTED
Cidara Therapeutics
CDTX
$2.32M 0.08%
14,324
– –
QURE icon
110
uniQure
QURE
$2.93B
$2.31M 0.08%
241,021
– –
MNK
111
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$2.31M 0.08%
61,900
– –
XLRN
112
DELISTED
Acceleron Pharma
XLRN
$2.23M 0.08%
59,654
– –
HR
113
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.2M 0.08%
68,000
– –
EVH icon
114
Evolent Health
EVH
$358M
$2.18M 0.08%
+122,500
New +$2.52M
ONCE
115
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.17M 0.08%
24,300
– –
GKOS icon
116
Glaukos
GKOS
$9.9B
$2.1M 0.08%
+63,707
New +$2.42M
HZNP
117
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.07M 0.07%
162,900
– –
GBT
118
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.94M 0.07%
62,500
-62,500
-50% -$1.76M
LKFT
119
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$1.93M 0.07%
19,000
– –
CASC
120
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.86M 0.07%
+453,900
New +$1.74M
NSTG
121
DELISTED
NanoString Technologies, Inc.
NSTG
$1.83M 0.07%
113,500
– –
BLUE
122
DELISTED
bluebird bio
BLUE
$1.82M 0.07%
1,025
– –
BCRX icon
123
BioCryst Pharmaceuticals
BCRX
$2.35B
$1.69M 0.06%
+323,255
New +$1.66M
CBAY
124
DELISTED
Cymabay Therapeutics
CBAY
$1.69M 0.06%
+209,962
New +$1.42M
ARGX icon
125
argenx
ARGX
$54.6B
$1.68M 0.06%
75,000
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
  • Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
  • Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
  • Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
  • Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
  • Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.